India's GlaxoSmithKline Pharma posts higher Q1 adjusted profit on strong demand
BENGALURU, Aug 2 (Reuters) -India's GlaxoSmithKline Pharmaceuticals GLAX.NS reported a higher first-quarter adjusted profit on Friday, driven by strong demand for its generic drugs and vaccines.
The Indian unit of British drugmaker GSKGSK.L reported a consolidated profit before tax and exceptional items of 2.49 billion rupees ($29.7 million) for the quarter ended June 30, compared with a profit of 1.64 billion rupees year ago.
The company had a one-time gain from the sale of surplus residential properties worth 173 million rupees in the year-ago period.
Its revenue from operations climbed 7% to 8.15 billion rupees in the latest quarter.
KEY CONTEXT
Earnings at drugmakers like GlaxoSmithKline Pharma have been pressured as prices of some of their key drugs were capped under the Indian government's essential medicines list (NLEM) since September 2022.
However, the company said that a rising market share of its key brands - Ceftum, Augmentin and Calpol - has helped it mitigate the impact of these price caps.
PEER COMPARISON
Estimates (next 12 months) | Analysts' sentiment | ||||||||
RIC | PE | EV/EBITDA | Revenue growth (%) | Profit growth (%) | Mean rating* | # of analysts | Stock to price target** | Div yield (%) | |
GlaxoSmithKline Pharmaceuticals | GLAX.NS | 54.83 | 40.19 | 9.77 | 48.58 | Buy | 4 | 1.02 | 1.16 |
Abbott India | ABOT.NS | 43.26 | 33.51 | 10.69 | 12.81 | Strong Buy | 4 | 0.97 | 1.44 |
Pfizer | PFIZ.NS | 38.18 | 30.52 | 6.92 | 15.39 | Buy | 3 | 1.10 | 0.62 |
Aurobindo Pharma | ARBN.NS | 20.57 | 11.79 | 9.19 | 15.66 | Buy | 25 | 1.08 | 0.31 |
APRIL TO JUNE STOCK PERFORMANCE
-- All data from LSEG
-- $1 = 83.7210 Indian rupees
APRIL TO JUNE STOCK PERFORMANCE https://tmsnrt.rs/3ylDPP6
Reporting by Kashish Tandon in Bengaluru; Editing by Savio D'Souza
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.